Scientists issue warning after making surprising findings in major rivers: 'Comes from everywhere'
"Alarming" levels of microplastics have been discovered in major rivers across Europe, according to researchers.
Scientists evaluated nine major European rivers, including the Thames and Tiber, and found microplastics in all of them, according to Phys.org.
On average, the team found three microplastics per cubic meter of water in each of the studied rivers.
Though this concentration is lower than the microplastic contamination found in the world's 10 most polluted rivers, the new study takes into account the volume of water flowing through the rivers. For instance, the fast flow of the Rhône in France translates into 3,000 plastic particles per second.
"What we see is the pollution is diffuse and established" and "comes from everywhere" in the rivers, French scientist Jean-François Ghiglione, who coordinated the study, told Phys.org.
Microplastics, or tiny plastic particles that result from the breakdown of larger plastics, pollute our waterways, soil, and air and can even be found in many of our foods and drinks. One study discovered these tiny plastic particles in more than 90% of protein sources studied, including beef and tofu.
These plastics have been linked to several health concerns, including reduced blood flow to the brain.
You can help reduce the amount of microplastics in the environment — and your exposure to them — by leaning on plastic-free alternatives such as reusable bottles and containers. Some major companies are making a difference by reducing the amount of plastic they produce. This includes McDonald's U.K., which recently banned all plastic cutlery.
Additionally, scientists are seeking ways to reduce microplastics in the environment. For instance, one team found a way to remove microplastics from drinking water using a material called CTF. Another group investigated using egg whites to remove these pollutants from water.
Do you think America has a plastic waste problem?
Definitely
Only in some areas
Not really
I'm not sure
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
5 Energizing Snack Recipes to Make Ahead and Eat All Week
The word 'snack' often conjures up images of indulgent treats and empty calories eaten for pure pleasure. But not only can mindful snacking be part of a healthy diet, but eating a nutritious mini-meal can help you sustain your energy levels throughout the day. Especially if you have a long lag between breakfast and lunch, or lunch and dinner. If you have a little time to meal prep, these make-ahead snack recipes are for you. Related: Whether you're hiking a forest trail or navigating the urban jungle (or jungle gym), keep a stash of this 3-ingredient trail mix on hand to maintain balanced energy levels throughout the day. The recipe calls for a trio of tropical ingredients: dried mango, coconut flakes, and cashews. Feel free to substitute any nuts you have on hand. Try the recipe from . Cucumber sandwiches are a staple of high tea. Perhaps it's because they're rich in Vitamin B5, which is known to help boost energy levels. We suggest you make this classic late-afternoon snack with whole wheat bread and a bit of Greek yogurt to double down on the energizing effects. Try the recipe from . This healthy take on Almond Joy candy bars is just the thing when you're craving something chocolatey. It just takes 15 minutes to whip up 40 sticky-sweet energy balls that will keep for a couple of weeks. Try the recipe from . If you've got a bag of edamame in your freezer and staples like olive oil, salt, and pepper in your pantry, you've got everything you need to bake up a batch of this addictive, high-protein snack that's so much better than store-bought. Try the recipe from . You don't have to follow the keto diet to love these low-carb turkey roll-ups. Just dab a tablespoon of tangy French onion spread on a slice of deli turkey, top it with a crunchy mix of cucumbers, bell peppers, and greens (or whatever other veggies you've got in the fridge), and roll for a super fresh and energizing snack. Try the recipe from . The post 5 Energizing Snack Recipes to Make Ahead and Eat All Week appeared first on Clean Plates. Related Headlines Why I'll never fly without Travelzoo — savings, perks, and peace of mind 5 Drinks High in Magnesium, Say Dietitians
Yahoo
9 hours ago
- Yahoo
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue originally appeared on TheStreet. Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. 💵💰💰💵 As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk () , while Eli Lilly () makes Zepbound and Mounjaro. One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's () and Domino's Pizza () . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 years Major restaurant chain quietly closes several locations Iconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. 'But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market,' said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients."Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $ Pizza, McDonald's rating surprise tied to persistent consumer issue first appeared on TheStreet on Jun 10, 2025 This story was originally reported by TheStreet on Jun 10, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
9 hours ago
- Newsweek
Long-Term Use of This Contraceptive Pill Linked to Increased Brain Tumor Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Using the progestogen-only contractive pill "desogestrel" for more than five years may increase the risk of developing a type of brain tumor known as an "intracranial meningioma," a new study has warned. The researchers noted that the risk is low—and is eliminated one year after desogestrel treatment is suspended—but that doctors' awareness of the possibility could eliminate the need for surgery in some cases. Meningiomas are a rare, non-cancerous form of tumor that arise from the membranes surrounding the brain. While slow-growing and benign in and of themselves, they can develop to a size that compresses other structures in the brain. They usually only require surgery when they cause symptoms such as persistent headaches or neurological issues. Woman holding combined oral contraceptive pill. Woman holding combined oral contraceptive pill. PATCHARIN SIMALHEK The study, based on data from France's national health system, compared over 8,000 women who underwent surgery for meningioma between 2020 and 2023 with more than 83,000 matched controls. Researchers found that women who had taken desogestrel continuously for more than five years had a slightly elevated risk of developing the brain tumors. Reassuringly, no increased risk was found for short-term use or for other commonly used progestogens like levonorgestrel, either alone or combined with estrogen. "This large study using French national database... shows [an] association between taking a certain progestogen (desogestrel) continuously for more than five years and meningioma risk, however, the magnitude of increase in the risk is small," said paper author Dr. Mangesh Thorat of Queen Mary University of London in a statement. Short-term use does not increase risk and the risk ceases after stopping use, he added. The authors estimate that one woman in every 67,000 using desogestrel would need surgery for meningioma and this drops to 1 in 17,000 with continuous use beyond five years. By comparison, breast cancer is about 10 times more common than meningioma. To understand progestogens, Thorat said it's crucial to note that the effects of different drug formulations can vary significantly and individual drugs can affect various organs differently. "Therefore, it is important to consider which specific drug is being used by an individual," he said. The study also showed that Microgynon and the morning-after pill—both containing levonorgestrel—were not linked to increased risk. Still, the findings have clinical relevance, especially for women over 45 or those with a prior history of using other high-risk progestogens. In such cases, the study suggests discontinuing desogestrel if a meningioma is identified, rather than jumping straight to surgery. "Stopping desogestrel may also avoid unnecessary potentially harmful treatments," said neurosurgeon Gilles Reuter of the University Hospital Liegein an accompanying editorial. Reuter emphasized that similar results have already been seen with other high-risk progestogens. While the study is observational and cannot prove cause and effect, its large sample size adds weight to the findings. However, experts say the takeaway should be caution, not alarm. For those affected by the findings, Thorat advises speaking with a healthcare provider regarding which drug is being used. "If it is associated with an increased risk of meningioma, this can be changed to a safer alternative," he said. "There is no reason to panic as the risk is very small and even in those who developed meningioma, stopping the specific drug has shown to cause regression in the size of meningioma." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about contraceptives? Let us know via health@ References Roland, N., Kolla, E., Baricault, B., Dayani, P., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2025). Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: National case-control study. BMJ, 389. Reuter, G. (2025). Progestogens and meningioma: New evidence on levonorgestrel and desogestrel. BMJ, 389.
